Xeris Biopharma Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xeris Biopharma Holdings (XERS).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$11Upside to Avg. PT+9.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$12→$14
Sep 10, 2026	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$12→$16
Aug 20, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$9→$12
Mar 2, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
Jan 9, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$9
Nov 7, 2025	Oppenheimer	Leland Gershell	Maintained	Outperform	$18
Nov 7, 2025	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
Nov 7, 2025	Piper Sandler	David Amsellem	PT Raise	Neutral	$6→$8
Oct 29, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$8→$18
Sep 17, 2025	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
Aug 19, 2025	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$7→$9
Aug 12, 2025	HC Wainwright & Co.	Brandon Folkes	Assumes	Buy	$10
Aug 8, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$7→$11
Aug 8, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$7→$8
Jun 5, 2025	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$6→$7
May 9, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$6→$7
Mar 7, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$5→$6
Mar 7, 2025	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$5→$6
Mar 7, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$5→$7

Analyst Ratings News

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $12 to $16.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9

Barclays analyst Glen Santangelo initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight rating and announces Price Target of $9.

Benzinga Newsdesk

Xeris Biopharma Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Xeris Biopharma Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PRO
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9

People Also Watch

People Also Watch

Xeris Biopharma Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Xeris Biopharma Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PROLeerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

PROBarclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

PROHC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PROHC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PROBarclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PRO
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9